Skip to main content
HYDROGEN STUDIESPOWERED BY ECHO WATER

Hydrogen and Bone Fracture Healing in Osteoporosis Drug Users in Rats

Hydrogen reshapes the senescent microenvironment of callus to enhance the healing of anti-osteoporotic-drug-induced atypical femoral fracture

Research hubs: Musculoskeletal System

This research was done in animals. Results in animals often don't carry over to people.

Scientific visualization of hydrogen therapy research for Hydrogen reshapes the senescent microenvironment of callus to enhance the healing of anti-osteoporotic-drug-induced atypical femoral fracture
Evidence type
Animal study (rat)
Authors
Yuanming An, Haozhi Zhang, Yuantao Zhang, Shi'an Zhang, Lizhen Zheng, Hongwei Shao, Wanting Du, Liming Cheng, Wei Sun, Jinhui Ma, Yechun Ruan, Jiankun Xu, Ling Qin
Journal
Biomaterials
Year
2026
Study Type
Rat
Delivery
Water (Electrolysis)
Dose
hydrogen rich water (HRW)
Outcome
Positive
Peer Reviewed
Yes
Cited by
1 (OpenAlex, as of November 2026)
Country
Germany

TL;DR

Hydrogen-rich water improved healing in a rat model of bisphosphonate-associated atypical femoral fracture by reducing local senescence, inflammation, fibrosis, and impaired blood vessel formation without weakening bisphosphonate-supported bone mass.

Key Finding

Hydrogen-rich water significantly promoted healing of bisphosphonate-induced atypical femoral fractures in rats by reversing cellular aging and shifting immune responses toward anti-inflammatory patterns at the fracture site.

Summary

This study used rats to investigate whether hydrogen-rich water could help heal a specific type of bone fracture that occurs as a side effect of long-term bisphosphonate drugs (medications used to treat osteoporosis). The researchers found that hydrogen-rich water promoted healing of these difficult-to-heal fractures by reducing cellular aging and inflammation at the fracture site, while maintaining the bone-strengthening benefits of the bisphosphonate medication.

Practical Takeaway

This rat study suggests hydrogen-rich water may have potential as a treatment for a specific fracture complication caused by osteoporosis medications, but human studies would be needed to determine if these results apply to people. The findings are preliminary and limited to animal research.

Abstract (excerpt)

Long-term bisphosphonates (BPs) are widely used to treat osteoporosis, however, they are paradoxically associated with the development of atypical femoral fractures (AFFs), which often characterized by impaired healing. In this study, we induced an AFF model using zoledronate (ZOL) administration…

Read the full abstract on PubMed